Brian Cheng
Stock Analyst at JP Morgan
(2.26)
# 2,735
Out of 5,147 analysts
73
Total ratings
45%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $30.09 | +52.87% | 1 | Feb 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $92 → $122 | $102.02 | +19.58% | 2 | Feb 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $91.35 | +36.84% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.20 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $92.08 | -12.03% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $13.78 | -63.72% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $12.77 | +40.96% | 5 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $23.29 | -1.25% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $2.78 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.30 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $2.74 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $27.73 | +19.00% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $58.80 | -20.07% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $28.94 | -30.89% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $60.14 | +16.40% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.79 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $21.86 | +0.64% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $24.75 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.20 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $8.21 | +301.95% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.52 | +294.74% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.25 | +5,558.85% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.10 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $7.25 | +1,224.14% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.94 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.42 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $8.23 | +932.81% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.75 | +140.00% | 1 | Aug 3, 2021 |
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $30.09
Upside: +52.87%
Revolution Medicines
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $102.02
Upside: +19.58%
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $91.35
Upside: +36.84%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.20
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $92.08
Upside: -12.03%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $13.78
Upside: -63.72%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $12.77
Upside: +40.96%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $23.29
Upside: -1.25%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.78
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.30
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.74
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $27.73
Upside: +19.00%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $58.80
Upside: -20.07%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $28.94
Upside: -30.89%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $60.14
Upside: +16.40%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.79
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $21.86
Upside: +0.64%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $24.75
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.20
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $8.21
Upside: +301.95%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.52
Upside: +294.74%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.25
Upside: +5,558.85%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.10
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $7.25
Upside: +1,224.14%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $0.94
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.42
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $8.23
Upside: +932.81%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.75
Upside: +140.00%